PresentationPablo CagnoniPresident and Head of Research & Development We're going to get started. Thank you, everyone, for joining us here in Berlin, and there are many more of you that are online. Welcome to the solid tumor update that we're having at ESMO 2025. We're very excited about 2 programs that we're going to talk about today. We're going to focus on 2 solid tumor programs, our TGF-beta receptor II by PD-1 bispecific and our KRAS G12D inhibitor. Data for both programs was presented here at ESMO. On ...